Study objective-The hepatitis delta virus (HDV) contributes significantly to the morbidity and mortality ofhepatitis B virus (HBV) infection, which is particularly prevalent among intravenous drug users and male homosexuals. A recent report has indicated that HDV first appeared in the South East London intravenous drug using population in 1982. The aim of the present study was to assess the prevalence of HDV in these two groups at risk of HBV infection in South East London.
Study objective-The hepatitis delta virus (HDV) contributes significantly to the morbidity and mortality ofhepatitis B virus (HBV) infection, which is particularly prevalent among intravenous drug users and male homosexuals. A recent report has indicated that HDV first appeared in the South East London intravenous drug using population in 1982. The aim of the present study was to assess the prevalence of HDV in these two groups at risk of HBV infection in South East London.
Design-The study was a cohort analysis of HBV and delta virus serum markers, stratified temporally and with respect to intravenous drug use and sexual practice.
Setting-This was a population study of 372 consecutive intravenous drug users attending a local drug rehabilitation centre and 1481 subjects seen at a sexually transmitted disease clinic in the same area, during the years 1979 to 1988.
Measurements and main results-Of 372 intravenous drug users, 195 (52-4%) had evidence of current or past infection with HBV, of whom 17 had chronic HBV infection-a carriage rate of 8-7%. Twelve (70 6%) of these 17 also had chronic HDV infection-the first cases being identified in 1984. By comparison, 406 (27-4%) of the sexually transmitted disease clinic patients had been been exposed to HBV, 32 having chronic HBV-a carriage rate of 7-9% (7 5% v 9-4% among male homosexuals v male heterosexuals). Ten Although the delta virus has been present in the British intravenous drug using population since at least 1976,4 a recent study5 in our neighbouring areas of Greenwich and Bexley indicated that the virus apparently did not arrive in south east London until 1982, whereupon it spread rapidly through the HBsAg positive intravenous drug using population-1600, of whom overall had evidence of delta virus infection.5
The purpose of the present study was to define the incidence and rates of HBV and HDV infection among intravenous drug users in south east London and to assess the relative risks by comparing these indices with findings in patients attending a sexually transmitted disease clinic in the same area.
Methods
The study cohort (table III) . Four others (two male) were seropositive for anti-HBs and total antiHDAg (table IV) . The remaining two patients (one male) had chronic HBV infection. Both of these were anti-HBe positive and neither had evidence of exposure to delta virus. The overall carriage rate among male heterosexuals with HBV markers was thus 9 4%/ , which is not significantly different (p > 0 8) from that in the male homosexual group.
Two of the further 100 anti-HBs positive non-intravenous drug users tested for delta virus markers were seropositive for total anti-HDAg. Both were male heterosexuals and were negative for IgM anti-HDAg (table IV) . By extrapolation (and including the HBsAg positive cases) it is estimated that 15 (3 700O) of the 406 patients who had been exposed to HBV may also have been exposed to HDv-a much lower frequency (p < 00005) than in the rehabilitation centre patients.
Overall, therefore, 10 (50o) of the 199 sexually transmitted disease clinic patients with HBV markers who were tested had serological evidence of exposure to HDV ( HBc), it is obvious that there are large numbers of individuals in these two populations who are at very high risk of acquiring HBV, and thus also HDV, infections.
Vaccination against hepatitis B has been widely available in the SE London area since 1986 but even today few of these individuals have received the vaccine. It is uncertain whether this is because of the cost involved or due to lack of awareness of the magnitude of the problem but, since there is apparently a pool of delta virus among intravenous drug users in the area and in view of the high cost in terms of morbidity and treatment of patients with HDV related liver disease, an active programme of vaccination against HBV in both the homosexual and intravenous drug using populations would seem desirable. It is recognised that HIV infection reduces the response to HBV vaccines and we are currently investigating the nature and extent of this hyporesponsiveness. However, the most recent data suggest that less than 500 of the London intravenous drug using population are currently infected with HIV,6 which is a very small proportion of the total at risk. The cost-effectivness of such a programme could be markedly increased by vaccinating those at risk as early as possible6 and by screening individuals for HBsAg and anti-HBs prior to vaccination to ensure that only those who had not been previously exposed to HBV received the vaccine.
